^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    90Y-besilesomab (TLX66)

    i
    Other names: TLX66, 90-Yttrium-labelled anti-CD66 monoclonal antibody, 90Yttrium-labelled anti-CD66 (BW250/183) monoclonal antibody, 90Y-labelled Anti-CD66 ab, TLX 66, TLX-66
    Associations

    News

    Trials
    Company:
    Great Ormond Street Hospital for Children, Telix
    Drug class:
    Beta radiation emitter, CEA inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Great Ormond Street Hospital for Children NHS Foundation Trust | Trial primary completion date: Jun 2023 --> Oct 2023
    Trial primary completion date
    |
    90Y-besilesomab (TLX66)